Actonel (risedronate) for osteoporosis

The FDA has now approved Actonel (risedronate) for osteoporosis. The HPB is considering this new indication for Canada.

Actonel is a bisphosphonate...similar to Fosamax (alendronate). But until now, Actonel was approved only for Paget's disease.

The new U.S. indication is to prevent or treat osteoporosis in postmenopausal women...or in patients taking glucocorticoids.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 120+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote